Sonnet biotherapeutics announces fda acceptance of the company's ind for the sb221 clinical trial of son-1010 combined with atezolizumab in the us

An ind was required to conduct the sb221 study of platinum-resistant ovarian cancer (proc) with the combination of sonnet's son-1010 and roche's atezolizumab (tecentriq ® ) in the us as part of the overall design of the program, the clinical trial was initiated at several sites in australia after hrec regulatory approval and tga notification the ind acceptance by fda allows for a global clinical effort, with the possibility for more rapid recruitment through the addition of us trial sites princeton, nj / accesswire / august 16, 2023 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the ind for sb221 (nct05756907), the phase 1b/2a clinical trial of son-1010(il12-fhab) in combination with roche's anti-pd-l1 checkpoint inhibitor, atezolizumab, has been accepted, and the study can begin in the us for the treatment of proc. the trial consists of a modified 3+3 dose-escalation design in part 1 to establish the maximum tolerated dose (mtd) of son-1010 with a fixed dose of atezolizumab.
SONN Ratings Summary
SONN Quant Ranking